Anti-angiogenic therapies: From theory to practice;Les thérapies anti-angiogéniques: de la théorie à la pratique

Annales de Biologie Clinique

Volumn 71, Issue 5, 2013, Pages 527-535

  Bidart, Marie ^a,b,c   Berger, François ^a,b,c   Pelletier, Laurent ^a,b,c  

^a Hopital Michallon   (France)

^b DIF   (France)

^c UNIV GRENOBLE ALPES   (France)

Author keywords

Angiogenesis; Anti angiogenic therapies; Cancers; Monoclonal antibodies; Resistance; Tyrosine kinase inhibitor

Indexed keywords

ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR;

ANGIOGENESIS; ANIMAL; ANTIANGIOGENIC THERAPY; ARTICLE; CLASSIFICATION; DRUG EFFECT; HUMAN; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PROFESSIONAL PRACTICE; RESISTANCE; STANDARD; THEORETICAL MODEL; VASCULARIZATION;

ANGIOGENESIS; ANTI-ANGIOGENIC THERAPIES; CANCERS; MONOCLONAL ANTIBODIES; RESISTANCE; TYROSINE KINASE INHIBITOR;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; MODELS, THEORETICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROFESSIONAL PRACTICE;

EID: 84887637692     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2013.0883     Document Type: Article

References (50)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971 18;285:1182-6.
2. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991;22:339-47.
3. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60. (Pubitemid 36749213)
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
5. Auguste P, Lemiere S, Larrieu-Lahargue F, Bikfalvi A. Molecular mechanisms of tumor vascularization. Crit Rev Oncol Hematol 2005;54:53-61. (Pubitemid 40387005)
6. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
7. Ferrara N, Hillan KJ, Gerber HP, NovotnyW. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400. (Pubitemid 38618122)
8. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
9. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49. (Pubitemid 351656458)
10. Coussens LM, RaymondWW,Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999;13:1382-97. (Pubitemid 29270244)
11. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-22. (Pubitemid 24097250)
12. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
13. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011;19:31-44.
14. Ronnov-Jessen L, PetersenOW,Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 1996;76:69-125. (Pubitemid 26048279)
15. De Wever O, Mareel M. Role of myofibroblasts at the invasion front. Biol Chem 2002;383:55-67. (Pubitemid 34224028)
16. Crawford Y, Ferrara N.Tumor and stromal pathways mediating refractoriness/ resistance to anti-angiogenic therapies. Trends Pharmacol Sci 2009;30:624-30.
17. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumorpromoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010;17:135-47.
18. Potenta S, Zeisberg E, Kalluri R. The role of endothelial-tomesenchymal transition in cancer progression. Br J Cancer 2008;99:1375-9.
19. Kamiya K, Konno H, Tanaka T, Baba M, Matsumoto K, Sakaguchi T, et al. Antitumor effect on human gastric cancer and induction of apoptosis by vascular endothelial growth factor neutralizing antibody. Jpn J Cancer Res 1999;90:794-800. (Pubitemid 29381111)
20. Shaheen RM, Tseng WW, Vellagas R, Liu W, Ahmad SA, Jung YD, et al. Effects of an antibody to vascular endothelial growth factor receptor- 2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int J Oncol 2001;18:221-6.
21. Liu Y, Poon RT, Li Q,KokTW,Lau C, Fan ST. Both antiangiogenesisand angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2005;65:3691-9. (Pubitemid 40616346)
22. Schmitz V, Wang L, Barajas M, Gomar C, Prieto J, Qian C. Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice. Gut 2004;53:561-7. (Pubitemid 38372982)
23. Oba K, Konno H, Tanaka T, Baba M, Kamiya K, Ohta M, et al. Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166. Cancer Lett 2002;175:45-51. (Pubitemid 33153043)
24. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002 19;94:883-93. (Pubitemid 34778087)
25. Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, et al. Combination of vascular endothelial growth factor receptor/plateletderived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 2008;14:2210-9. (Pubitemid 351551134)
26. Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC. Drug insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery. Nat Clin Pract Oncol 2006;3:682-92. (Pubitemid 44843126)
27. Dallas NA, Fan F, Gray MJ, Van Buren G, 2nd, Lim SJ, Xia L, et al. Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells. Cancer Metastasis Rev 2007;26:433-41. (Pubitemid 350115100)
28. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999;5:2963-70. (Pubitemid 29493976)
29. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer 2008;8:579-91.
30. Rini BI. Sorafenib. Expert Opin Pharmacother 2006;7:453-61.
31. Motzer RJ, Hoosen S, Bello CL, Christensen JG. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 2006;15:553-61.
32. Mitchell A, Adams LA, MacQuillan G, Tibballs J, vanden Driesen R, Delriviere L. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 2008;14:210-3. (Pubitemid 351267278)
33. Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012;307:948-55.
34. Beecken WD, Fernandez A, Joussen AM, Achilles EG, Flynn E, Lo KM, et al. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J Natl Cancer Inst 2001;93:382-7. (Pubitemid 32229382)
35. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
36. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
37. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
38. Padera TP, Kuo AH, Hoshida T, Liao S, Lobo J, Kozak KR, et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther 2008;7:2272-9.
39. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21.
40. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 2011;108:3749-54.
41. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
42. Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010;13:16-28.
43. Kindler HL. Pancreatic cancer: an update. Curr Oncol Rep 2007;9:170-6. (Pubitemid 46736349)
44. Gerhardt H, Semb H. Pericytes: gatekeepers in tumour cell metastasis ? J Mol Med (Berl) 2008;86:135-44. (Pubitemid 351172122)
45. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309. (Pubitemid 41443415)
46. Graepler F, Verbeek B, Graeter T, Smirnow I, Kong HL, Schuppan D, et al. Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology 2005;41:879-86. (Pubitemid 40462951)
47. Hurwitz H, Fehrenbacher L, NovotnyW, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. (Pubitemid 38702844)
48. Nieder C, Wiedenmann N, Andratschke N, Molls M. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 2006;32:348-64. (Pubitemid 44063875)
49. Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, et al. SU5416 and SU6668 attenuate the angiogenic effects of radiationinduced tumor cell growth factor production and amplify the direct antiendothelial action of radiation in vitro. Cancer Res 2003;63:3755-63. (Pubitemid 36793064)
50. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 2011;11:135-41.